Fig. 1: Figure showing overall survival (OS) differences between ASXL1, SF3B1 and JAK2 V617F mutated and wild-type MDS/MPN-RS-T patients. | Blood Cancer Journal

Fig. 1: Figure showing overall survival (OS) differences between ASXL1, SF3B1 and JAK2 V617F mutated and wild-type MDS/MPN-RS-T patients.

From: Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients

Fig. 1

A shows that there is no significant Kaplan–Meier estimate of OS difference between ASXL1 mutated and wild-type MDS/MPN-RS-T patients [median OS, 4.7 (95% CI 0.3–10.5) versus 5.7 (95% CI 2.5–8.4) years, P = 0.7], B shows that there is no significant Kaplan–Meier estimate of OS difference between SF3B1 mutated and wild-type MDS/MPN-RS-T patients [median OS, 6.3 (95% CI 5.4–9) versus 4.3 (95% CI 0.8–11.3) years, P = 0.4], C shows that there is no significant Kaplan–Meier estimate of OS difference between JAK2 V617F mutated and wild-type MDS/MPN-RS-T patients [median OS, 6.3 (95% CI 1.1–9.1) versus 5.6 (95% CI 2.3–10.5) years, P = 0.7].

Back to article page